Holleypharm has signed an agreement for artemisinin with the William J. Clinton Foundation, agreeing to lower the price of a leading artemisinin-based combination therapy for malaria by 30% and reduce the price volatility of artemisinin, the key raw material for this and other ACTs, by 70%.
According to the agreement, Holleypharm will regularly supply artemisinin as raw material for other enterprises that have also signed long term agreements, to ensure that the market price of artemisinin and compound preparations is in a reasonable range.
The reduced prices will be available to the 69 countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV/AIDS Initiative purchasing consortium.
